Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

199.56 +1.10 (+0.56%)
Streaming Delayed Price Updated: 11:56 AM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP).... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price... 
Via Benzinga
Analyst Ratings For Ascendis Pharma
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
Via Benzinga
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
ASND earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
Upgrades For Iridium Communications Inc (NASDAQ:IRD... 
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back... 
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and... 
Via Talk Markets
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (... 
Via Benzinga
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
ASND earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
63 Biggest Movers From Yesterday
Gainers Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume. TSR, Inc. (NASDAQ: TSRI) shares rose 28.1% to close at $11... 
Via Benzinga
Why Shares of Ascendis Soared This Week
The pharmaceutical company saw its shares jump more than $26. 
Via The Motley Fool
Mid-Afternoon Market Update: Pure Storage Rises Following Strong Q2 Results; SelectQuote Shares Plunge
Toward the end of trading Thursday, the Dow traded down 0.38% to 35,270.96 while the NASDAQ fell 0.35% to 14,988.64. The S&P also fell, dropping 0.40% to 4,483.22. The U.S.... 
Via Benzinga
Topics Stocks
Here's Why Ascendis Pharma Shares Are Surging Higher Today
Approval of the company's weekly growth hormone is making investors smile today. 
Via The Motley Fool
What 8 Analyst Ratings Have To Say About Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings w... 
Via Benzinga
Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher
Midway through trading Thursday, the Dow traded down 0.33% to 35,288.79 while the NASDAQ fell 0.62% to 14,948.24. The S&P also fell, dropping 0.53% to 4,472.56. The U.S. has... 
Via Benzinga
Topics Stocks
45 Stocks Moving In Thursday's Mid-Day Session
Gainers Blue Water Acquisition Corp. (NASDAQ: BLUW) shares climbed 57% to $16.41. Blue Water Acquisition is expected to hold a special meeting of its stockholders on Friday,... 
Via Benzinga
See Why Ascendis Pharma Stock Is Shining On Thursday
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the... 
Via Benzinga
Ascendis Stock Surges To 6-Month High; FDA Approval Lands It In A Major Market
Ascendis Pharma won FDA approval to treat children with insufficient growth hormone, and the biotech stock rocketed on Thursday. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Mixed; Dollar General Profit Beats Views
Following the market opening Thursday, the Dow traded up 0.15% to 35,458.00 while the NASDAQ rose 0.02% to 15,044.79. The S&P, however, dropped 0.12% to 4,490.91. The U.S. has... 
Via Benzinga
Topics Stocks
Recap: Ascendis Pharma Q2 Earnings
Shares of Ascendis Pharma (NASDAQ:ASND) rose 23.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 38.71% year over... 
Via Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) stock increased by 22.69% to $151.73 during Thursday's pre-market session. The company's market cap stands at $8.1 billion.... 
Via Benzinga
22 Stocks Moving in Thursday's Pre-Market Session
Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) st... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.